21.75
Precedente Chiudi:
$21.73
Aprire:
$21.88
Volume 24 ore:
432.76K
Relative Volume:
0.94
Capitalizzazione di mercato:
$1.29B
Reddito:
-
Utile/perdita netta:
$-85.21M
Rapporto P/E:
-11.51
EPS:
-1.89
Flusso di cassa netto:
$-68.53M
1 W Prestazione:
+2.16%
1M Prestazione:
+18.01%
6M Prestazione:
+35.35%
1 anno Prestazione:
-22.65%
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Nome
Enliven Therapeutics Inc
Settore
Industria
Telefono
720-647-8519
Indirizzo
6200 LOOKOUT ROAD, BOULDER
Confronta ELVN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ELVN
Enliven Therapeutics Inc
|
21.75 | 1.19B | 0 | -85.21M | -68.53M | -1.89 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-16 | Iniziato | Goldman | Buy |
2024-12-13 | Iniziato | BTIG Research | Buy |
2024-09-09 | Iniziato | H.C. Wainwright | Buy |
2024-06-11 | Iniziato | Robert W. Baird | Outperform |
2024-04-09 | Iniziato | Mizuho | Buy |
2023-03-29 | Iniziato | Jefferies | Buy |
Mostra tutto
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
Heatmap analysis for Enliven Therapeutics Inc. and competitorsChart Signals & AI Enhanced Market Trend Forecasts - newser.com
Enliven Therapeutics (NASDAQ:ELVN) Trading 8.1% Higher – Time to Buy? - Defense World
Tools to monitor Enliven Therapeutics Inc. recovery probabilityRecession Risk & Daily Profit Maximizing Tips - newser.com
How to read the order book for Enliven Therapeutics Inc.2025 Support & Resistance & Fast Gain Swing Alerts - newser.com
Published on: 2025-10-15 02:57:52 - newser.com
Enliven Therapeutics Inc. recovery potential after sell off2025 Price Momentum & Free Expert Approved Momentum Trade Ideas - newser.com
Real time breakdown of Enliven Therapeutics Inc. stock performanceEntry Point & Free Technical Confirmation Trade Alerts - newser.com
What the charts say about Enliven Therapeutics Inc. todayShort Setup & Daily Volume Surge Trade Alerts - newser.com
Strategies to average down on Enliven Therapeutics Inc.July 2025 Patterns & Expert Curated Trade Setups - newser.com
Automated trading signals detected on Enliven Therapeutics Inc.Trade Exit Summary & Consistent Return Investment Signals - newser.com
Chart based exit strategy for Enliven Therapeutics Inc.July 2025 Fed Impact & Daily Stock Trend Reports - newser.com
Enliven Therapeutics (NASDAQ:ELVN) Trading 6.1% HigherHere's Why - MarketBeat
Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) COO Sells 6,667 Shares of Stock - MarketBeat
Volatility clustering patterns for Enliven Therapeutics Inc.Rate Cut & Free Weekly Watchlist of Top Performers - newser.com
Is a relief rally coming for Enliven Therapeutics Inc. holdersWeekly Trade Analysis & High Accuracy Swing Entry Alerts - newser.com
Long term hold vs stop loss in Enliven Therapeutics Inc.2025 Top Decliners & Daily Profit Focused Stock Screening - newser.com
Enliven Therapeutics (NASDAQ:ELVN) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Using Ichimoku Cloud for Enliven Therapeutics Inc. technicals2025 Analyst Calls & Consistent Growth Equity Picks - newser.com
Enliven Therapeutics COO Patel sells $133,992 in stock By Investing.com - Investing.com South Africa
Enliven Therapeutics COO Patel sells $133,992 in stock - Investing.com
Short interest data insights for Enliven Therapeutics Inc.Market Activity Report & Real-Time Volume Spike Alerts - newser.com
What moving averages say about Enliven Therapeutics Inc.Market Activity Report & Low Risk Growth Stock Ideas - newser.com
Why retail investors favor Enliven Therapeutics Inc. stockQuarterly Growth Report & Free Safe Capital Growth Stock Tips - newser.com
Is now a turning point for Enliven Therapeutics Inc.2025 Volatility Report & Smart Money Movement Alerts - newser.com
Enliven Therapeutics stock falls after pricing capital raise of $200M via securities offering - MSN
Developing predictive dashboards with Enliven Therapeutics Inc. dataStop Loss & Weekly Sector Rotation Insights - newser.com
Will Enliven Therapeutics Inc. rebound enough to break evenJuly 2025 Snapshot & Reliable Intraday Trade Alerts - newser.com
Top chart patterns to watch in Enliven Therapeutics Inc.July 2025 Retail & Risk Managed Investment Signals - newser.com
Will Enliven Therapeutics Inc. stock recover after recent drop2025 Earnings Impact & Precise Swing Trade Alerts - newser.com
Benjamin Hohl Sells 3,250 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $81,000.00 in Stock - MarketBeat
Enliven Therapeutics CFO sells $22,524 in stock - MSN
Enliven Therapeutics Inc Azioni (ELVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Enliven Therapeutics Inc Azioni (ELVN) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Sep 29 '25 |
Option Exercise |
2.48 |
3,250 |
8,060 |
26,250 |
Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Sep 29 '25 |
Sale |
20.40 |
3,250 |
66,291 |
23,000 |
Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER |
Sep 26 '25 |
Sale |
20.25 |
4,000 |
81,005 |
927,688 |
Kintz Samuel | PRESIDENT AND CEO |
Sep 26 '25 |
Sale |
20.06 |
3,700 |
74,228 |
915,392 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):